HROW
Harrow
HROW and HROWM • NASDAQ
Harrow is a medical - pharmaceuticals company in the healthcare sector trading on NASDAQ, led by CEO Mark L. Baum, with a market cap of $1.3B.
CEOMark L. Baum
Next Earnings
Upcoming earnings announcement for Harrow
Date
Thursday, May 7, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.31
Revenue Estimate
$58.8M
Earnings History
Past 12 earnings reports for Harrow
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | Q4 2025 | $0.17Est: $0.45 | -62.2% | $89.1MEst: $88.6M | +0.6% |  10-K |
| Nov 10, 2025 | Q3 2025 | $0.33Est: $0.22 | +50.0% | $71.6MEst: $73.0M | -1.8% | 10-Q |
| Aug 11, 2025 | Q2 2025 | $0.24Est: $0.04 | +500.0% | $63.7MEst: $65.7M | -3.0% | 10-Q |
| May 8, 2025 | Q1 2025 | -$0.38Est: $0.01 | -3900.0% | $47.8MEst: $57.0M | -16.1% | 10-Q |
| Mar 27, 2025 | Q4 2024 | $0.40Est: $0.13 | +207.7% | $66.8MEst: $61.8M | +8.1% | 10-K |
| Nov 13, 2024 | Q3 2024 | -$0.05Est: -$0.05 | 0.0% | $49.3MEst: $52.8M | -6.7% | 10-Q |
| Aug 7, 2024 | Q2 2024 | -$0.06Est: -$0.07 | +14.3% | $48.9MEst: $49.1M | -0.4% | 10-Q |
| May 13, 2024 | Q1 2024 | -$0.28Est: -$0.20 | -40.0% | $34.6MEst: $37.3M | -7.2% | 10-Q |
| Mar 19, 2024 | Q4 2023 | -$0.20Est: -$0.04 | -400.0% | $36.4MEst: $37.9M | -4.0% | 10-K |
| Nov 13, 2023 | Q3 2023 | -$0.09Est: $0.04 | -325.0% | $34.3MEst: $37.6M | -8.8% | — |
| Aug 9, 2023 | Q2 2023 | -$0.02Est: -$0.04 | +50.0% | $33.5MEst: $31.0M | +7.8% | 10-Q |
| May 11, 2023 | Q1 2023 | -$0.03Est: -$0.05 | +40.0% | $26.1MEst: $25.2M | +3.8% | — |